Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: A retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT)

U De Giorgi, S Richard, M Badoglio, E Kanfer, JH Bourrhis, E Nicolas-Virelizier, K Vettenranta, B Lioure, S Martin, P Dreger, MK Schuler, K Thomson, E Scarpi, G Rosti, F Selle, G Mangili, F Lanza, M Bregni, on behalf of the Solid Tumours Working Party (STWP) of the EBMT

Research output: Contribution to journalArticle

Abstract

Background: High-dose chemotherapy (HDC) with hematopoietic progenitor cell transplantation is a standard option for relapsed/refractory testicular germ-cell tumor (GCT), but only few data have been reported in female patients with GCT. We conducted a retrospective analysis of female patients with GCT treated with HDC and registered with the European Society for Blood and Marrow Transplantation. Patients and methods: Between 1985 and 2013, 60 registered female patients with GCT, median age 27 years (range 15-48), were treated with salvage HDC. Forty patients (67%) had primary ovarian GCT, 8 (13%) mediastinal, 7 (12%) retroperitoneal and 5 (8%) other primary sites/unknown. Twenty-two patients (37%) received HDC as second-line therapy, 29 (48%) as third-line, and 9 (15%) as fourth- to sixth-line. Nine of 60 patients (15%) received HDC as late-intensification with no evidence of metastasis before HDC. The conditioning HDC regimens comprised carboplatin in 51 of 60 cases (85%), and consisted of a single HDC cycle in 31 cases (52%), a multi-cycle HDC regimen in 29 (48%). Results: Nine cases who underwent late intensification HDC were not evaluable for response. Of the other 51 assessable patients, 17 (33%) achieved a complete response (CR), 8 (16%) a marker-negative partial remission (PRm-), 5 (10%) a marker-positive partial remission, 5 (10%) stable disease, and 13 (25%) progressive disease. There were 3 toxic deaths (6%). With an overall median follow-up of 14 months (range 1-219), 7 of 9 (78%) patients with late intensification and 18 of the 25 patients (72%) achieving a CR/PRm- following HDC were free of relapse/progression. In total, 25 of 60 patients (42%) were progression-free following HDC at a median follow-up of 87 months (range 3-219 months). Conclusions: Salvage HDC based on carboplatin represents a therapeutic option for female patients with relapsed/refractory GCT. © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
Original languageEnglish
Pages (from-to)1910-1916
Number of pages7
JournalAnnals of Oncology
Volume28
Issue number8
DOIs
Publication statusPublished - 2017

Fingerprint

Germ Cell and Embryonal Neoplasms
Drug Therapy
Carboplatin
Poisons
Cell Transplantation
Hematopoietic Stem Cells
Transplantation
Bone Marrow

Cite this

Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: A retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT). / De Giorgi, U; Richard, S; Badoglio, M; Kanfer, E; Bourrhis, JH; Nicolas-Virelizier, E; Vettenranta, K; Lioure, B; Martin, S; Dreger, P; Schuler, MK; Thomson, K; Scarpi, E; Rosti, G; Selle, F; Mangili, G; Lanza, F; Bregni, M; EBMT, on behalf of the Solid Tumours Working Party (STWP) of the.

In: Annals of Oncology, Vol. 28, No. 8, 2017, p. 1910-1916.

Research output: Contribution to journalArticle

De Giorgi, U, Richard, S, Badoglio, M, Kanfer, E, Bourrhis, JH, Nicolas-Virelizier, E, Vettenranta, K, Lioure, B, Martin, S, Dreger, P, Schuler, MK, Thomson, K, Scarpi, E, Rosti, G, Selle, F, Mangili, G, Lanza, F, Bregni, M & EBMT, OBOTSTWPSTWPOT 2017, 'Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: A retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT)', Annals of Oncology, vol. 28, no. 8, pp. 1910-1916. https://doi.org/10.1093/annonc/mdx259
De Giorgi, U ; Richard, S ; Badoglio, M ; Kanfer, E ; Bourrhis, JH ; Nicolas-Virelizier, E ; Vettenranta, K ; Lioure, B ; Martin, S ; Dreger, P ; Schuler, MK ; Thomson, K ; Scarpi, E ; Rosti, G ; Selle, F ; Mangili, G ; Lanza, F ; Bregni, M ; EBMT, on behalf of the Solid Tumours Working Party (STWP) of the. / Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: A retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT). In: Annals of Oncology. 2017 ; Vol. 28, No. 8. pp. 1910-1916.
@article{865deb55e765439cad86d88bf0c1e737,
title = "Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: A retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT)",
abstract = "Background: High-dose chemotherapy (HDC) with hematopoietic progenitor cell transplantation is a standard option for relapsed/refractory testicular germ-cell tumor (GCT), but only few data have been reported in female patients with GCT. We conducted a retrospective analysis of female patients with GCT treated with HDC and registered with the European Society for Blood and Marrow Transplantation. Patients and methods: Between 1985 and 2013, 60 registered female patients with GCT, median age 27 years (range 15-48), were treated with salvage HDC. Forty patients (67{\%}) had primary ovarian GCT, 8 (13{\%}) mediastinal, 7 (12{\%}) retroperitoneal and 5 (8{\%}) other primary sites/unknown. Twenty-two patients (37{\%}) received HDC as second-line therapy, 29 (48{\%}) as third-line, and 9 (15{\%}) as fourth- to sixth-line. Nine of 60 patients (15{\%}) received HDC as late-intensification with no evidence of metastasis before HDC. The conditioning HDC regimens comprised carboplatin in 51 of 60 cases (85{\%}), and consisted of a single HDC cycle in 31 cases (52{\%}), a multi-cycle HDC regimen in 29 (48{\%}). Results: Nine cases who underwent late intensification HDC were not evaluable for response. Of the other 51 assessable patients, 17 (33{\%}) achieved a complete response (CR), 8 (16{\%}) a marker-negative partial remission (PRm-), 5 (10{\%}) a marker-positive partial remission, 5 (10{\%}) stable disease, and 13 (25{\%}) progressive disease. There were 3 toxic deaths (6{\%}). With an overall median follow-up of 14 months (range 1-219), 7 of 9 (78{\%}) patients with late intensification and 18 of the 25 patients (72{\%}) achieving a CR/PRm- following HDC were free of relapse/progression. In total, 25 of 60 patients (42{\%}) were progression-free following HDC at a median follow-up of 87 months (range 3-219 months). Conclusions: Salvage HDC based on carboplatin represents a therapeutic option for female patients with relapsed/refractory GCT. {\circledC} The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.",
author = "{De Giorgi}, U and S Richard and M Badoglio and E Kanfer and JH Bourrhis and E Nicolas-Virelizier and K Vettenranta and B Lioure and S Martin and P Dreger and MK Schuler and K Thomson and E Scarpi and G Rosti and F Selle and G Mangili and F Lanza and M Bregni and EBMT, {on behalf of the Solid Tumours Working Party (STWP) of the}",
year = "2017",
doi = "10.1093/annonc/mdx259",
language = "English",
volume = "28",
pages = "1910--1916",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "8",

}

TY - JOUR

T1 - Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: A retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT)

AU - De Giorgi, U

AU - Richard, S

AU - Badoglio, M

AU - Kanfer, E

AU - Bourrhis, JH

AU - Nicolas-Virelizier, E

AU - Vettenranta, K

AU - Lioure, B

AU - Martin, S

AU - Dreger, P

AU - Schuler, MK

AU - Thomson, K

AU - Scarpi, E

AU - Rosti, G

AU - Selle, F

AU - Mangili, G

AU - Lanza, F

AU - Bregni, M

AU - EBMT, on behalf of the Solid Tumours Working Party (STWP) of the

PY - 2017

Y1 - 2017

N2 - Background: High-dose chemotherapy (HDC) with hematopoietic progenitor cell transplantation is a standard option for relapsed/refractory testicular germ-cell tumor (GCT), but only few data have been reported in female patients with GCT. We conducted a retrospective analysis of female patients with GCT treated with HDC and registered with the European Society for Blood and Marrow Transplantation. Patients and methods: Between 1985 and 2013, 60 registered female patients with GCT, median age 27 years (range 15-48), were treated with salvage HDC. Forty patients (67%) had primary ovarian GCT, 8 (13%) mediastinal, 7 (12%) retroperitoneal and 5 (8%) other primary sites/unknown. Twenty-two patients (37%) received HDC as second-line therapy, 29 (48%) as third-line, and 9 (15%) as fourth- to sixth-line. Nine of 60 patients (15%) received HDC as late-intensification with no evidence of metastasis before HDC. The conditioning HDC regimens comprised carboplatin in 51 of 60 cases (85%), and consisted of a single HDC cycle in 31 cases (52%), a multi-cycle HDC regimen in 29 (48%). Results: Nine cases who underwent late intensification HDC were not evaluable for response. Of the other 51 assessable patients, 17 (33%) achieved a complete response (CR), 8 (16%) a marker-negative partial remission (PRm-), 5 (10%) a marker-positive partial remission, 5 (10%) stable disease, and 13 (25%) progressive disease. There were 3 toxic deaths (6%). With an overall median follow-up of 14 months (range 1-219), 7 of 9 (78%) patients with late intensification and 18 of the 25 patients (72%) achieving a CR/PRm- following HDC were free of relapse/progression. In total, 25 of 60 patients (42%) were progression-free following HDC at a median follow-up of 87 months (range 3-219 months). Conclusions: Salvage HDC based on carboplatin represents a therapeutic option for female patients with relapsed/refractory GCT. © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

AB - Background: High-dose chemotherapy (HDC) with hematopoietic progenitor cell transplantation is a standard option for relapsed/refractory testicular germ-cell tumor (GCT), but only few data have been reported in female patients with GCT. We conducted a retrospective analysis of female patients with GCT treated with HDC and registered with the European Society for Blood and Marrow Transplantation. Patients and methods: Between 1985 and 2013, 60 registered female patients with GCT, median age 27 years (range 15-48), were treated with salvage HDC. Forty patients (67%) had primary ovarian GCT, 8 (13%) mediastinal, 7 (12%) retroperitoneal and 5 (8%) other primary sites/unknown. Twenty-two patients (37%) received HDC as second-line therapy, 29 (48%) as third-line, and 9 (15%) as fourth- to sixth-line. Nine of 60 patients (15%) received HDC as late-intensification with no evidence of metastasis before HDC. The conditioning HDC regimens comprised carboplatin in 51 of 60 cases (85%), and consisted of a single HDC cycle in 31 cases (52%), a multi-cycle HDC regimen in 29 (48%). Results: Nine cases who underwent late intensification HDC were not evaluable for response. Of the other 51 assessable patients, 17 (33%) achieved a complete response (CR), 8 (16%) a marker-negative partial remission (PRm-), 5 (10%) a marker-positive partial remission, 5 (10%) stable disease, and 13 (25%) progressive disease. There were 3 toxic deaths (6%). With an overall median follow-up of 14 months (range 1-219), 7 of 9 (78%) patients with late intensification and 18 of the 25 patients (72%) achieving a CR/PRm- following HDC were free of relapse/progression. In total, 25 of 60 patients (42%) were progression-free following HDC at a median follow-up of 87 months (range 3-219 months). Conclusions: Salvage HDC based on carboplatin represents a therapeutic option for female patients with relapsed/refractory GCT. © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

U2 - 10.1093/annonc/mdx259

DO - 10.1093/annonc/mdx259

M3 - Article

VL - 28

SP - 1910

EP - 1916

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 8

ER -